1. 1. R. M. Lovell et al., Global Prevalence of an Risk Factors for Irritable Bowel Syndrome: A Meta-Analysis, Clin. gastroenterol Hepatol. 2012; 10:712-7212.
  2. 2. P. Enck et al., Irritable bowel syndrome, Nature Reviews Disease Primers article number: 16014 doi:10.1038/nrdp.2016.14
  3. 3. T. Piche, Tight junctions and IBS – the link between epithelial permeability, low-grade inflammation, and symptom generation ?, Neurogastroenterol Motil 2014, 26: 296-302
  4. 4. A.Kerckhoffs et al., Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients, World J Gastroenterol 2009, 15(23): 2887-2892 5.
  5. 5. N. Piqué et al., Xyloglucan, a Plant Polymer with Barrier Protective Properties over the Mucous Membranes: An Overview, Int. J. Mol. Sci. 2018, 19,673; doi:10.3390/ijms19030673
  6. 6. Agnieszka Kosinska et al., Interactions between tannins and proteins isolated from broad bean seeds (Vicia faba Major) yield soluble and non-soluble complexes, Eur Food Res Technol 2011; 233:213–222 DOI 10.1007/s00217-011-1506-9
  7. 7. G. Gibson et al., Dietary Modulation of the Human Colonic Microbiota: Introducing the Concept of Prebiotics, J. Nutr. 1995; 125: 1401-1412
  8. 8. K. Scott et al., Prebiotic stimulation of human colonic butyrate-producing bacteria and bifidobacteria, in vitro, FEMS Microbiol Ecol 2014; 87: 30-40 9.
  9. 9. Gebruiksaanwijzing Gelsectan®
  10. 10. Trifan A. et al., Efficacy and safety of Gelsectan® for diarrhoea-predominant irritable bowel syndrome: A randomised, crossover clinical trial, United European Gastroenterology Journal 2019, Vol. 7(8): 1093–1101